Association between vaccination and the risk of immunoglobulin A vasculitis in children.
10.7499/j.issn.1008-8830.2303129
- Author:
Feng CAO
1
;
Long-Wei XU
1
;
Ying-Hui ZHANG
1
Author Information
1. Department of Nephrology and Rheumatology, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou 450000, China.
- Publication Type:Journal Article
- Keywords:
Case-crossover analysis;
Child;
Immunoglobulin vasculitis;
Risk;
Vaccination
- MeSH:
Humans;
Child;
Retrospective Studies;
Immunoglobulin A;
IgA Vasculitis;
Vaccination;
Vaccines
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(11):1137-1142
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To study the effect of vaccination on the short-term risk of immunoglobulin A vasculitis (IgAV) in children.
METHODS:A retrospective analysis was conducted on the general data and the vaccination history within one year prior to onset in children with IgAV hospitalized in the Children's Hospital Affiliated to Zhengzhou University from November 2021 to January 2023. Vaccine exposure rates in the risk period (3 months prior to IgAV onset) and the control period were compared by autocontrol-case crossover analysis, and the odds ratio and 95% confidence interval (95%CI) were calculated. A sensitivity analysis for the one-month and two-month risk periods was conducted.
RESULTS:A total of 193 children with IgAV were included, with a median age of 7.0 years. Among the 193 children, 36 (18.7%) received at least one dose of the vaccine within 1 year prior to IgAV onset, and 14 (7.3%) received at least one dose of the vaccine during the 3-month risk period. Compared to the unvaccinated IgAV group, the vaccinated IgAV group had a significantly younger age of onset (P<0.05). There were no significant differences in the proportions of children with gastrointestinal involvement, renal involvement, and joint involvement between the two groups (P>0.05). The odds ratio for developing IgAV after receiving any type of vaccine within 3 months prior to IgAV onset was 2.08 (95%CI: 0.82-5.27, P>0.05). Further sensitivity analysis for the 1-month and 2-month risk periods demonstrated that the odds ratios for developing IgAV after receiving any type of vaccine were 2.74 (95%CI: 0.72-10.48, P>0.05) and 2.72 (95%CI: 0.95-7.77, P>0.05), respectively.
CONCLUSIONS:Vaccination dose not increase the risk of IgAV, nor does it exacerbate clinical symptoms in children with IgAV.
